About
Overview
Management Team
Board of Directors
Scientific Advisors
Investors
Platform
Overview
Publications
Pipeline
Pipeline
Manufacturing
Partnering
News & Events
Press releases
In the News
Events
Working Here
Contact us
Menu
Menu
News & Events
Press Releases
Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
13 November 2024
/
by Freddie Kerner
Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
7 October 2024
/
by Freddie Kerner
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
27 August 2024
/
by Freddie Kerner
Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies
9 July 2024
/
by Freddie Kerner
Microbiotica announces clinical trial collaboration with MSD to evaluate MB097 in combination with KEYTRUDA
®
(pembrolizumab) in a phase 1b clinical trial in melanoma
12 April 2023
/
by immunocity
Microbiotica announces transition of leadership
29 November 2022
/
by immunocity
Microbiotica to present at key industry conferences in Q3 2022
20 June 2022
/
by immunocity
Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic
5 April 2022
/
by immunocity
Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
7 March 2022
/
by immunocity
Page 1 of 5
1
2
3
4
5
Scroll to top